Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
Background AML1/ETO fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of AML1/ETO fusion on the efficacy of venetoclax in the treatment of AML is unclear. Objective The aim of this study was to evaluate the efficacy of ve...
Gespeichert in:
| Veröffentlicht in: | Targeted oncology 2024-03, Vol.19 (2), p.237-249 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 2 |
| container_start_page | 237 |
| container_title | Targeted oncology |
| container_volume | 19 |
| creator | Jin, Dian Chen, Haoguang He, Jingsong Li, Yi Zheng, Gaofeng Yang, Yang Zhao, Yi Le, Jing Shu, Wenxiu He, Donghua Cai, Zhen |
| description | Background
AML1/ETO
fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of
AML1/ETO
fusion on the efficacy of venetoclax in the treatment of AML is unclear.
Objective
The aim of this study was to evaluate the efficacy of venetoclax plus hypomethylating agents (VEN/HMAs) in patients with
AML1/ETO
-positive AML.
Patients and Methods
Patients with newly diagnosed AML in two centers were reviewed and divided into three cohorts:
AML1/ETO
-positive AML treated with frontline VEN/HMA (Cohort A),
AML1/ETO
-negative AML treated with frontline VEN/HMA (Cohort B), or
AML1/ETO
-positive AML treated with frontline IC (Cohort C). The response and survival were compared between the cohorts.
Results
A total of 260 patients were included in the study. Patients in Cohort A had a significantly lower overall response rate (ORR) than patients in Cohort B (40.9% vs 71.2%,
p
= 0.005). The median event-free survival (EFS) in Cohort A and Cohort B was 2.7 months and 7.7 months, respectively, with no significant difference. The ORR and median EFS in Cohort C were 80.8% and 14.9 months, respectively, which were significantly superior to those in Cohort A, and the advantages remained significant after propensity score matching. ORR and EFS in
KIT
-mutated patients with
AML1/ETO
-positive AML receiving VEN/HMA were much inferior to those in
KIT
wild-type patients (ORR 0.0% vs 81.8%,
p
= 0.001; EFS 1.2 months vs not reached,
p
|
| doi_str_mv | 10.1007/s11523-024-01039-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10963532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2956162917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-cb9179113eea9ff1841bf1d567538563adbecd76a0fb4032d7360bd263f2f4cc3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwAiyQJTZsQv3vyQqNypRWmlIWBbGzHOc645LY0zgBsuFZeBaeDJdpy88C6Uq-0v3u8bk6RfGU4JcEY3WYCBGUlZjyEhPMqnK-V-wTpWRJJf54_7YXldwrHqV0iTFXVOCHxR5bcCkFk_vFt9N-a-yIokPLszU5XF2co-Mp-RhQrnEDaOWct8bO18gHCDBG25mv6F03JXQyb2MP42buzOhDi5YthDEhH358fwtfuhm99qYNMUGDlnYaAZ3N0EXfoDVMn6D35nHxwJkuwZOb96B4f7y6ODop1-dvTo-W69JyJcbS1hVRFSEMwFTOkQUntSONkEqwhZDMNDXYRkmDXc0xo41iEtcNlcxRx61lB8Wrne52qntobLY5mE5vB9-bYdbReP33JPiNbuNnTXAlmWA0K7y4URji1QRp1L1PFrrOBIhT0rQSkkiafWb0-T_oZZyGkO_L1EJwRimvMkV3lB1iSgO4OzcE6-t89S5fnfPVv_LVc1569ucddyu3gWaA7YCUR6GF4fff_5H9CQh5szc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2985432249</pqid></control><display><type>article</type><title>Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Jin, Dian ; Chen, Haoguang ; He, Jingsong ; Li, Yi ; Zheng, Gaofeng ; Yang, Yang ; Zhao, Yi ; Le, Jing ; Shu, Wenxiu ; He, Donghua ; Cai, Zhen</creator><creatorcontrib>Jin, Dian ; Chen, Haoguang ; He, Jingsong ; Li, Yi ; Zheng, Gaofeng ; Yang, Yang ; Zhao, Yi ; Le, Jing ; Shu, Wenxiu ; He, Donghua ; Cai, Zhen</creatorcontrib><description>Background
AML1/ETO
fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of
AML1/ETO
fusion on the efficacy of venetoclax in the treatment of AML is unclear.
Objective
The aim of this study was to evaluate the efficacy of venetoclax plus hypomethylating agents (VEN/HMAs) in patients with
AML1/ETO
-positive AML.
Patients and Methods
Patients with newly diagnosed AML in two centers were reviewed and divided into three cohorts:
AML1/ETO
-positive AML treated with frontline VEN/HMA (Cohort A),
AML1/ETO
-negative AML treated with frontline VEN/HMA (Cohort B), or
AML1/ETO
-positive AML treated with frontline IC (Cohort C). The response and survival were compared between the cohorts.
Results
A total of 260 patients were included in the study. Patients in Cohort A had a significantly lower overall response rate (ORR) than patients in Cohort B (40.9% vs 71.2%,
p
= 0.005). The median event-free survival (EFS) in Cohort A and Cohort B was 2.7 months and 7.7 months, respectively, with no significant difference. The ORR and median EFS in Cohort C were 80.8% and 14.9 months, respectively, which were significantly superior to those in Cohort A, and the advantages remained significant after propensity score matching. ORR and EFS in
KIT
-mutated patients with
AML1/ETO
-positive AML receiving VEN/HMA were much inferior to those in
KIT
wild-type patients (ORR 0.0% vs 81.8%,
p
= 0.001; EFS 1.2 months vs not reached,
p
< 0.001).
Conclusions
Newly diagnosed AML patients with
AML1/ETO
fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients with
AML1/ETO
-positive AML, IC should be preferred over VEN/HM.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-024-01039-y</identifier><identifier>PMID: 38466536</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomedicine ; Bridged Bicyclo Compounds, Heterocyclic ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncogene Proteins, Fusion - genetics ; Oncology ; Original ; Original Research Article ; Prognosis ; Progression-Free Survival ; Retrospective Studies ; Sulfonamides</subject><ispartof>Targeted oncology, 2024-03, Vol.19 (2), p.237-249</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-cb9179113eea9ff1841bf1d567538563adbecd76a0fb4032d7360bd263f2f4cc3</citedby><cites>FETCH-LOGICAL-c475t-cb9179113eea9ff1841bf1d567538563adbecd76a0fb4032d7360bd263f2f4cc3</cites><orcidid>0000-0001-6026-3804</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11523-024-01039-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11523-024-01039-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38466536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jin, Dian</creatorcontrib><creatorcontrib>Chen, Haoguang</creatorcontrib><creatorcontrib>He, Jingsong</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zheng, Gaofeng</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Le, Jing</creatorcontrib><creatorcontrib>Shu, Wenxiu</creatorcontrib><creatorcontrib>He, Donghua</creatorcontrib><creatorcontrib>Cai, Zhen</creatorcontrib><title>Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><addtitle>Target Oncol</addtitle><description>Background
AML1/ETO
fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of
AML1/ETO
fusion on the efficacy of venetoclax in the treatment of AML is unclear.
Objective
The aim of this study was to evaluate the efficacy of venetoclax plus hypomethylating agents (VEN/HMAs) in patients with
AML1/ETO
-positive AML.
Patients and Methods
Patients with newly diagnosed AML in two centers were reviewed and divided into three cohorts:
AML1/ETO
-positive AML treated with frontline VEN/HMA (Cohort A),
AML1/ETO
-negative AML treated with frontline VEN/HMA (Cohort B), or
AML1/ETO
-positive AML treated with frontline IC (Cohort C). The response and survival were compared between the cohorts.
Results
A total of 260 patients were included in the study. Patients in Cohort A had a significantly lower overall response rate (ORR) than patients in Cohort B (40.9% vs 71.2%,
p
= 0.005). The median event-free survival (EFS) in Cohort A and Cohort B was 2.7 months and 7.7 months, respectively, with no significant difference. The ORR and median EFS in Cohort C were 80.8% and 14.9 months, respectively, which were significantly superior to those in Cohort A, and the advantages remained significant after propensity score matching. ORR and EFS in
KIT
-mutated patients with
AML1/ETO
-positive AML receiving VEN/HMA were much inferior to those in
KIT
wild-type patients (ORR 0.0% vs 81.8%,
p
= 0.001; EFS 1.2 months vs not reached,
p
< 0.001).
Conclusions
Newly diagnosed AML patients with
AML1/ETO
fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients with
AML1/ETO
-positive AML, IC should be preferred over VEN/HM.</description><subject>Biomedicine</subject><subject>Bridged Bicyclo Compounds, Heterocyclic</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Research Article</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Retrospective Studies</subject><subject>Sulfonamides</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEoqXwAiyQJTZsQv3vyQqNypRWmlIWBbGzHOc645LY0zgBsuFZeBaeDJdpy88C6Uq-0v3u8bk6RfGU4JcEY3WYCBGUlZjyEhPMqnK-V-wTpWRJJf54_7YXldwrHqV0iTFXVOCHxR5bcCkFk_vFt9N-a-yIokPLszU5XF2co-Mp-RhQrnEDaOWct8bO18gHCDBG25mv6F03JXQyb2MP42buzOhDi5YthDEhH358fwtfuhm99qYNMUGDlnYaAZ3N0EXfoDVMn6D35nHxwJkuwZOb96B4f7y6ODop1-dvTo-W69JyJcbS1hVRFSEMwFTOkQUntSONkEqwhZDMNDXYRkmDXc0xo41iEtcNlcxRx61lB8Wrne52qntobLY5mE5vB9-bYdbReP33JPiNbuNnTXAlmWA0K7y4URji1QRp1L1PFrrOBIhT0rQSkkiafWb0-T_oZZyGkO_L1EJwRimvMkV3lB1iSgO4OzcE6-t89S5fnfPVv_LVc1569ucddyu3gWaA7YCUR6GF4fff_5H9CQh5szc</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Jin, Dian</creator><creator>Chen, Haoguang</creator><creator>He, Jingsong</creator><creator>Li, Yi</creator><creator>Zheng, Gaofeng</creator><creator>Yang, Yang</creator><creator>Zhao, Yi</creator><creator>Le, Jing</creator><creator>Shu, Wenxiu</creator><creator>He, Donghua</creator><creator>Cai, Zhen</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6026-3804</orcidid></search><sort><creationdate>20240301</creationdate><title>Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia</title><author>Jin, Dian ; Chen, Haoguang ; He, Jingsong ; Li, Yi ; Zheng, Gaofeng ; Yang, Yang ; Zhao, Yi ; Le, Jing ; Shu, Wenxiu ; He, Donghua ; Cai, Zhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-cb9179113eea9ff1841bf1d567538563adbecd76a0fb4032d7360bd263f2f4cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biomedicine</topic><topic>Bridged Bicyclo Compounds, Heterocyclic</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Research Article</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Retrospective Studies</topic><topic>Sulfonamides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jin, Dian</creatorcontrib><creatorcontrib>Chen, Haoguang</creatorcontrib><creatorcontrib>He, Jingsong</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zheng, Gaofeng</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhao, Yi</creatorcontrib><creatorcontrib>Le, Jing</creatorcontrib><creatorcontrib>Shu, Wenxiu</creatorcontrib><creatorcontrib>He, Donghua</creatorcontrib><creatorcontrib>Cai, Zhen</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jin, Dian</au><au>Chen, Haoguang</au><au>He, Jingsong</au><au>Li, Yi</au><au>Zheng, Gaofeng</au><au>Yang, Yang</au><au>Zhao, Yi</au><au>Le, Jing</au><au>Shu, Wenxiu</au><au>He, Donghua</au><au>Cai, Zhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><addtitle>Target Oncol</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>19</volume><issue>2</issue><spage>237</spage><epage>249</epage><pages>237-249</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Background
AML1/ETO
fusion confers favorable prognosis in acute myeloid leukemia (AML) treated with intensive chemotherapy (IC). However, the impact of
AML1/ETO
fusion on the efficacy of venetoclax in the treatment of AML is unclear.
Objective
The aim of this study was to evaluate the efficacy of venetoclax plus hypomethylating agents (VEN/HMAs) in patients with
AML1/ETO
-positive AML.
Patients and Methods
Patients with newly diagnosed AML in two centers were reviewed and divided into three cohorts:
AML1/ETO
-positive AML treated with frontline VEN/HMA (Cohort A),
AML1/ETO
-negative AML treated with frontline VEN/HMA (Cohort B), or
AML1/ETO
-positive AML treated with frontline IC (Cohort C). The response and survival were compared between the cohorts.
Results
A total of 260 patients were included in the study. Patients in Cohort A had a significantly lower overall response rate (ORR) than patients in Cohort B (40.9% vs 71.2%,
p
= 0.005). The median event-free survival (EFS) in Cohort A and Cohort B was 2.7 months and 7.7 months, respectively, with no significant difference. The ORR and median EFS in Cohort C were 80.8% and 14.9 months, respectively, which were significantly superior to those in Cohort A, and the advantages remained significant after propensity score matching. ORR and EFS in
KIT
-mutated patients with
AML1/ETO
-positive AML receiving VEN/HMA were much inferior to those in
KIT
wild-type patients (ORR 0.0% vs 81.8%,
p
= 0.001; EFS 1.2 months vs not reached,
p
< 0.001).
Conclusions
Newly diagnosed AML patients with
AML1/ETO
fusion had a poor response to frontline VEN/HMA treatment. When determining induction therapy for patients with
AML1/ETO
-positive AML, IC should be preferred over VEN/HM.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38466536</pmid><doi>10.1007/s11523-024-01039-y</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-6026-3804</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1776-2596 |
| ispartof | Targeted oncology, 2024-03, Vol.19 (2), p.237-249 |
| issn | 1776-2596 1776-260X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10963532 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biomedicine Bridged Bicyclo Compounds, Heterocyclic Humans Leukemia Leukemia, Myeloid, Acute - drug therapy Medical prognosis Medicine Medicine & Public Health Oncogene Proteins, Fusion - genetics Oncology Original Original Research Article Prognosis Progression-Free Survival Retrospective Studies Sulfonamides |
| title | Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T23%3A58%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20AML1/ETO%20Fusion%20on%20the%20Efficacy%20of%20Venetoclax%20Plus%20Hypomethylating%20Agents%20in%C2%A0Newly%20Diagnosed%20Acute%20Myeloid%20Leukemia&rft.jtitle=Targeted%20oncology&rft.au=Jin,%20Dian&rft.date=2024-03-01&rft.volume=19&rft.issue=2&rft.spage=237&rft.epage=249&rft.pages=237-249&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-024-01039-y&rft_dat=%3Cproquest_pubme%3E2956162917%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2985432249&rft_id=info:pmid/38466536&rfr_iscdi=true |